Protara Therapeutics Announces Third Quarter 2026 Financial Results and Provides a Business Update
Globe Newswire•06/11/2026•08:00 ET
0
Key Highlights
- ➤$143.1 million cash, equivalents and marketable debt securities fund planned operations into 2028
- ➤TARA-002 ADVANCED-2 BCG-Unresponsive enrollment expected to complete in Q4 2026
- ➤TARA-002 STARBORN-1 enrollment now expected to complete early Q1 2027
- ➤Rolling BLA submission for TARA-002 in lymphatic malformations planned for 2H 2027
- ➤$8.75 million Novex asset purchase brings TARA-002 manufacturing in-house
- ➤Q3 net loss $21.7 million, or $0.35 per share, versus $13.3 million loss
Expert Statements
Jesse Shefferman, Chief Executive Officer of Protara Therapeutics
“Protara continues to deliver across our late-stage portfolio, advancing each of our programs toward its next key clinical and regulatory milestone. This steady progress positions us to close out the year with strong momentum and sets the stage for an impactful 2027”
Jesse Shefferman, Chief Executive Officer of Protara Therapeutics
“TARA-002 has the potential to be a preferred treatment option for patients with non-muscle invasive bladder cancer (NMIBC), and we are on track to complete enrollment of the BCG-Unresponsive registrational cohort by year-end, a key step toward bringing this therapy to patients. Following quarter end, we also entered into a purchase agreement for TARA-002 manufacturing-related assets from Novex Innovations, LLC, our clinical supply partner since 2019. We are excited to bring this manufacturing capability in-house as we advance our late-stage clinical trials and prepare to launch TARA-002 in lymphatic malformations (LMs) and NMIBC.”
Jesse Shefferman, Chief Executive Officer of Protara Therapeutics
“Turning to our rare disease pipeline, we now expect to complete enrollment of the registrational STARBORN-1 trial of TARA-002 in LMs early in the first quarter of 2027. Supported by the program’s Breakthrough Therapy designation, we remain on track to initiate our rolling Biologics License Application (BLA) submission in the second half of 2027. We also completed enrollment of the Phase 2b portion of the THRIVE-3 trial of IV Choline Chloride and look forward to reporting interim results by the end of this year.”
Expect to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial of TARA-002 in NMIBC by year-end 2026
Enrollment in registrational STARBORN-1 trial now expected to complete in early 1Q 2027; expect to initiate a rolling BLA submission for TARA-002 in LMs in 2H 2027
Get started
Create a free account to read the full story.